Roche Elecsys SFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(k) Clearance, Offering a Fast and Reliable Way to Predict the Risk of Developing Severe Preeclampsia

PR NewswireFeb 13 09:00 ET

Roche's Growth Fueled by Key Drugs, Promising Pipeline -- Market Talk

WSJFeb 13 06:43 ET

Roche Holding Raised to Buy From Neutral by UBS

Dow JonesFeb 13 04:15 ET · Ratings

Roche Holding Target Raised to CHF338 From CHF300 by UBS

Dow JonesFeb 13 04:15 ET · Ratings

FDA Approves Genentech's Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

BusinesswireFeb 12 11:45 ET

Zhongtai International: Maintains INNOVENT BIO 'Buy' rating, Target Price raised to HKD 43.85.

Zhuhai International released a research report stating that it maintains its "Buy" rating for INNOVENT BIO (01801), with the Target Price raised from HKD 42.45 to HKD 43.85 based on the adjusted DCF model. The company expects that the initial launch of Ma Shidu Peptide may increase sales promotions, and therefore, the sales expense forecast for 2025E has been raised by 9.3%. However, due to an increase in total revenue forecasts, the Shareholder Net income forecasts for 2025-26E have been raised by 0.1% and 4.6% respectively. Zhuhai International's main points are as follows: The company's product sales revenue is expected to grow rapidly in 2024 as planned, as recently announced for the full-year product sales in 2024.

新浪港股Feb 11 22:59 ET